

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

KERYX BIOPHARMACEUTICALS INC

Form 8-K

December 24, 2002

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 23, 2002

Keryx Biopharmaceuticals, Inc.
(Exact name of registrant as specified in charter)

Delaware	000-30929	13-4087132
-----	-----	-----
(State or other juris- diction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

101 Main Street, 17th Floor, Cambridge, MA	02142
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (617) 494-5515

N/A
(Former name or former address, if changed since last report)

Item 5. Other Events.

On December 23, 2002, Keryx Biopharmaceuticals, Inc. announced the appointment of Michael S. Weiss as its Chairman and Chief Executive Officer, replacing Dr. Benjamin Corn, who resigned his position as President and Chief Executive Officer effective on December 23, 2002. On December 23, 2002, Keryx also announced that Dr. Morris Laster, its Executive Chairman, resigned his position effective immediately.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits

The exhibit filed as part of this Current Report on Form 8-K is listed on the Exhibit Index immediately preceding such exhibit, which Exhibit Index is incorporated herein by reference.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

Date: December 24, 2002

KERYX BIOPHARMACEUTICALS, INC.

By: /s/ Michael S. Weiss

Michael S. Weiss
Chairman and Chief Executive
Officer

EXHIBIT INDEX

Exhibit No.

99.1

Description

Press release dated December 23, 2002